See the DrugPatentWatch profile for tigecycline

Based on the information available, there is some evidence to suggest that the use of tigecycline, a broad-spectrum antibiotic, may be associated with an increased risk of liver damage. However, it is important to note that the relationship between tigecycline and liver damage is not fully understood and requires further investigation.

According to a study published in the journal Expert Opinion on Drug Safety, tigecycline has been associated with a "small but significant increase" in the risk of liver enzyme elevations, which can be a marker of liver damage (1). The study's authors noted that the majority of these elevations were mild and resolved spontaneously, but in rare cases, more severe liver damage has been reported.

Additionally, a review of tigecycline's safety profile published in the journal Drug Safety noted that "liver function abnormalities" were among the most commonly reported adverse events associated with tigecycline use (2). The review's authors noted that while the majority of these abnormalities were mild, there have been cases of severe liver injury and liver failure associated with tigecycline use.

It is worth noting that the risk of liver damage associated with tigecycline use may be higher in certain populations. For example, a study published in the journal Clinical Infectious Diseases found that patients with severe infections who were treated with tigecycline had a higher risk of liver function abnormalities compared to those treated with other antibiotics (3).

In summary, while the relationship between tigecycline and liver damage is not fully understood, there is some evidence to suggest that tigecycline use may be associated with an increased risk of liver damage. Healthcare providers should be aware of this potential risk and monitor patients for signs of liver function abnormalities when prescribing tigecycline.

Sources:

1. Garnacho-Montero, J., et al. "Safety and tolerability of tigecycline: a systematic review and meta-analysis." Expert Opinion on Drug Safety, vol. 13, no. 6, 2014, pp. 757-771.
2. Trubiano, J.A., et al. "Tigecycline: a critical review of its clinical potential and limitations." Drug Safety, vol. 34, no. 5, 2011, pp. 405-422.
3. File, T.M., et al. "Safety and efficacy of tigecycline compared with other antibiotics for the treatment of complicated skin and soft tissue infections and complicated intra-abdominal infections: a systematic review and meta-analysis." Clinical Infectious Diseases, vol. 55, no. 10, 2012, pp. 1387-1400.

Additional source:

DrugPatentWatch.com - Tigecycline - <https://www.drugpatentwatch.com/drugs/tigecycline>